Elicio Therapeutics, Inc. (ELTX) stock
ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.43−0.05 (-3.38%)
Close on Nov 17, 2026Market cap $37.58MP/E –Yield –
Elicio Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Elicio Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$37.69M. For fiscal 2025 it was -$36.95M. The highest annual figure on record is -$22.18M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.95M | – |
| FY2024 | Dec 31, 2024 | -$37.07M | – |
| FY2023 | Dec 31, 2023 | -$32.69M | – |
| FY2022 | Dec 31, 2022 | -$22.18M | – |
| FY2021 | Dec 31, 2021 | -$52.64M | – |
| FY2020 | Dec 31, 2020 | -$22.89M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$11.65M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.80M | – |
| Q3 FY2025 | Sep 30, 2025 | -$11.09M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.95M | – |
| Q1 FY2025 | Mar 31, 2025 | -$10.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$8.93M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.12M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.90M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.19M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.48M | -254.4% |
| Q1 FY2023 | Mar 31, 2023 | -$8.14M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.39M | – |
| Q2 FY2022 | Jun 30, 2022 | $6.14M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.36M | -169.7% |
| Q3 FY2021 | Sep 30, 2021 | -$15.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.55M | – |
| Q4 FY2020 | Dec 31, 2020 | $20.59M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.94M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.80M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.73M | – |
See a number that looks wrong?